Nuvation Bio Inc.
NUVB NYSE· Pharmaceutical Preparations
Last close · Oct 27, 2026
$4.55
KIRA · Stoqly’s AI analyst, in plain words
- Nuvation Bio Inc. had $62.9M of revenue in fiscal 2025, up 699.0% on the year before.
- Its operating margin was −338.7%, up 7,188.6 pts: of every 100 in sales, about −339 is left after running the business.
- Nuvation Bio Inc. lost $205M in fiscal 2025.
- Nuvation Bio Inc. has $476M more cash than debt.
Market cap
$1.6M
P/E
—
Revenue
$62.9M
Net income
−$205M
Free cash flow
—
Operating margin
−338.7%
Nuvation Bio Inc. in 30 seconds · fiscal 2025
Are sales growing?
+699.0%
Yes. Sales grew 699.0% last year.
Does it make a profit?
−325.3%
No. It lost money last year.
How healthy are the accounts?
3 / 8
Weak. It passes 3 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Nuvation Bio Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- Nuvation Bio Inc.
- CIK
- 0001811063
Nuvation Bio Inc. · NUVB
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | — | $0.0M | $7.9M | $62.9M |
| Revenue growth | — | — | — | — | 699.0% |
| Gross margin | — | — | — | 10.1% | — |
| Operating margin | — | — | — | −7,527.3% | −338.7% |
| Net income | −$86.8M | −$104M | −$75.8M | −$568M | −$205M |
| Net margin | — | — | — | −7,213.8% | −325.3% |
| Diluted EPS | −$0.44 | −$0.48 | −$0.35 | −$2.11 | −$0.60 |
| Cash | |||||
| Cash from operations | −$68.2M | −$96.1M | −$68.0M | −$130M | −$173M |
| Share count change | −99.8% | 9.5% | 1.0% | 22.8% | 27.0% |
| Debt and strength | |||||
| Cash and short-term investments | $765M | $661M | $611M | $503M | $529M |
| Debt incl. finance leases | — | — | $0.0M | $6.3M | $52.9M |
| Shareholders' equity | $746M | $655M | $605M | $464M | $306M |
| Current ratio | 45.6x | 50.7x | 44.1x | 9.0x | 7.0x |
| Interest coverage | — | — | — | −1,737.9x | −15.6x |
| Returns and quality | |||||
| Return on equity | −18.1% | −14.9% | −12.0% | −106.3% | −53.2% |
| Return on tangible equity | −11.6% | −15.9% | −12.5% | −123.7% | −69.5% |
| Piotroski F-score | — | — | — | 2 | 3 |
| Altman Z'' | 30.9 | 44.2 | 42.3 | −0.8 | −2.0 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$7.0M
6 insiders
Of sales under plans
49%
$3.5M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nuvation Bio Inc. · NUVB
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.55 a share, the company is worth $1.6M.
Source: SEC EDGAR XBRL filings (CIK 0001811063). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.